[Roentgen-surgical interventions in combined treatment of patients, suffering hepatic metastases of noncolorectal cancer].

Results of combined treatment, using roentgen-surgical interventions, of 58 patients, suffering noncolorectal metastatic affection of the liver, complicated in 20 (34.5%) of them by obturation jaundice, were analyzed. While resectability of the metastases, preoperatively chemotherapy (CHT) or chemoembolization of hepatic artery (CHEHA) in 1 - 2 courses were performed, and then - hepatic resection of various volume, adjuvant regional CHEHA or systemic CHT.

[Roentgensurgical interventions in combined treatment of patients for hepatic metastases of colorectal cancer].

The results of combined treatment in 82 patients for hepatic metastases of colorectal cancer, complicated in 14 (17.1%) of them by obturation jaundice, using roentgensurgical interventions, were analyzed. In case of resectable metastases, preoperative chemotherapy and chemoembolization of hepatic artery was conducted, using 1 - 2 courses of oxaliplatin, and further--hepatic resection in various volume (in 23 patients), adjuvant regional chemoembolization or systemic chemotherapy.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

This two-arm, randomised, multicentre, open-label, phase IIIb study investigated the safety and efficacy of a 3-h catumaxomab infusion with/without prednisolone premedication to reduce catumaxomab-related adverse events. Patients with malignant ascites due to epithelial cancer received four 3-h intraperitoneal catumaxomab infusions with/without intravenous prednisolone (25 mg) premedication before each infusion. The primary safety endpoint was a composite safety score calculated from the incidence and intensity of the most frequent catumaxomab-related adverse events (pyrexia, nausea, vomiting and abdominal pain).

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.

[Enhancement of efficiency in the chemotherapy of ovarian cancer].

As many as 308 patients with stage IV ovarian carcinoma (OC) were examined to assess effectiveness of employing platinum drugs (CP and CAP)-based chemotherapy regimens depending on the degree of differentiation of tumor cells, on the extent to which the process has been disseminated, and on the cytostatics regimens adopted. Standard chemotherapy regimens permitting maintaining the standard "intensity" of the cytostatic dose have been shown to improve OC treatment results, especially in those patients presenting with medium and high-grade (poorly differentiated) tumors. Patients with low-grade tumors derive benefit when placed on the above chemotherapy at 4 weeks intervals whereas those with medium- and high-grade tumors benefit from treatments on a 3-week interval schedule.